Welcome to our dedicated page for Sol Gel Technolg news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol Gel Technolg stock.
Sol Gel Technologies Ltd (SLGL) is a clinical-stage pharmaceutical innovator focused on advancing topical dermatology treatments through its proprietary silica-based microencapsulation technology. This page aggregates all official company announcements, including updates on acne and rosacea therapies in development.
Investors and industry professionals will find timely updates on regulatory milestones, clinical trial progress, and strategic partnerships. The curated news collection provides insights into SLGL's pipeline advancements and commercialization efforts for its controlled-release drug delivery platform.
Key updates include earnings reports, FDA correspondence, licensing agreements, and research breakthroughs. All content is sourced directly from company filings and verified press releases to ensure accuracy.
Bookmark this page for streamlined access to SLGL's latest developments in dermatological innovation. Check regularly for authoritative updates on this clinical-stage leader's progress in enhancing topical treatment efficacy and safety.
Sol-Gel Technologies (NASDAQ: SLGL) has entered into a significant asset purchase agreement with Shenzhen Beimei Pharmaceutical Co. to commercialize TWYNEO® for acne vulgaris in mainland China, Hong Kong, Macau, Taiwan, and Israel.
Sol-Gel will receive up to $15 million, including $10 million in upfront and regulatory milestone payments, with the remaining $5 million as royalties on net sales. This agreement enhances the potential reach of TWYNEO beyond the U.S. market.
Beimei will handle the registration and commercialization of TWYNEO in these regions. This strategic move aims to address the unmet clinical need in the acne market, particularly among adolescents in China.
FAQ
What is the current stock price of Sol Gel Technolg (SLGL)?
What is the market cap of Sol Gel Technolg (SLGL)?
